Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12678723 | 0.90 | CASR (0.36) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL3166382 | 0.89 | PTGDR2 (0.39) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL3169132 | 0.82 | EPHX2 (0.40) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL4425058 | 0.82 | CASR (0.37) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL12678725 | 0.75 | PTGDR2 (0.40) | PTGDR2EPHX2ALDH1A1 | |
| SCHEMBL3169588 | 0.73 | EPHX2 (0.41) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL4430019 | 0.71 | GPR52 (0.38) | EPHX2ALDH1A1 | |
| SCHEMBL12678728 | 0.69 | POLB (0.45) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL3164868 | 0.68 | PTGDR2 (0.40) | CASRPTGDR2GLP1RGCGREPHX2 | |
| SCHEMBL3159511 | 0.68 | EPHX2 (0.51) | CASRPTGDR2GLP1RGCGREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | CASR 1220/4885PTGDR2 116/4885GLP1R 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.